Search

Search Constraints

You searched for: Author/Creator Gitlitz, Barbara

Search Results

1. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016)

2. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016)

3. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016. (16th November 2016)

4. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Issue 10308 (9th October 2021)

5. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib. Issue 2 (May 2015)

6. Pertuzumab and Erlotinib in Patients With Relapsed Non-Small Cell Lung Cancer: A Phase II Study Using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging. (23rd January 2014)

7. Pertuzumab and Erlotinib in Patients With Relapsed Non‐Small Cell Lung Cancer: A Phase II Study Using 18F‐Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging. (23rd January 2014)

8. Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs. Issue 1 (December 2017)